STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZVRA
  4. [Form 4] ZEVRA THERAPEUTICS, INC. Insider Trading Activity

Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Zevra Therapeutics, Inc. reported that Chief Legal & Compliance Officer Rahsaan Thompson exercised equity awards and sold shares. On June 21, 2026, he exercised 66,667 restricted stock units, receiving the same number of common shares at a stated price of $0.00 per share. After this exercise, his direct holdings were 114,792 common shares. On June 22, 2026, he completed an open-market sale of 34,557 common shares at a weighted average price of $12.6835 per share, leaving him with 80,235 common shares held directly. Footnotes explain that each restricted stock unit converts into one common share and outline a vesting schedule for the RSU grant, as well as a referenced Rule 10b5-1(c) plan adoption date.

Positive

  • None.

Negative

  • None.
Insider Thompson Rahsaan
Role Chief Legal & Compliance
Sold 34,557 shs ($438K)
Type Security Shares Price Value
Sale Common Stock 34,557 $12.6835 $438K
Exercise Restricted Stock Unit 66,667 $0.00 --
Exercise Common Stock 66,667 $0.00 --
Holdings After Transaction: Common Stock — 80,235 shares (Direct); Restricted Stock Unit — 66,667 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Adoption date of referenced 10b5-1(c) plan is: 01-08-2026. This transaction was executed in multiple trades at prices ranging from $12.53 to $13.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, and the remaining tranche of the restricted stock units will vest and settle on the next anniversary thereafter, subject to the Reporting person's continued service through such vesting date.
Open-market sale 34,557 shares at $12.6835 Common Stock sale on June 22, 2026
RSU exercise 66,667 shares at $0.00 Restricted Stock Unit conversion on June 21, 2026
Shares after exercise 114,792 shares Direct common stock holdings after RSU exercise
Shares after sale 80,235 shares Direct common stock holdings after open-market sale
Net buy/sell direction net-sell of 34,557 shares Transaction summary across reported trades
10b5-1 plan adoption date January 8, 2026 Referenced Rule 10b5-1(c) trading plan footnote
restricted stock unit financial
"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Rule 10b5-1(c) plan regulatory
"Adoption date of referenced 10b5-1(c) plan is: 01-08-2026."
open-market sale financial
"transaction_action: "open-market sale" with transaction_code "S" for Common Stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" with transaction_code "M" for Restricted Stock Unit."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transactions did ZVRA’s Rahsaan Thompson report in this Form 4?
Rahsaan Thompson reported exercising 66,667 restricted stock units into common shares and then selling 34,557 common shares in an open-market transaction, ending with 80,235 common shares held directly after these transactions.

How many Zevra Therapeutics (ZVRA) shares did Rahsaan Thompson sell and at what price?
He sold 34,557 shares of Zevra Therapeutics common stock in an open-market transaction at a weighted average price of $12.6835 per share, with individual trades executed between $12.53 and $13.19 according to the footnote.

How many Zevra Therapeutics shares does Rahsaan Thompson hold after these transactions?
Following the RSU exercise and subsequent sale, Rahsaan Thompson directly holds 80,235 shares of Zevra Therapeutics common stock, as reported in the post-transaction ownership column for the open-market sale entry in the Form 4 data.

Was a Rule 10b5-1 trading plan referenced in Rahsaan Thompson’s ZVRA filing?
Yes. A footnote states that the adoption date of the referenced Rule 10b5-1(c) plan is January 8, 2026. This disclosure indicates the presence of a pre-arranged trading plan associated with the reported equity activity.

What does the vesting schedule look like for the ZVRA restricted stock units exercised?
Footnote disclosure explains that the first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, with the remaining tranche scheduled to vest on the next anniversary, subject to continued service.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Thompson Rahsaan
(Last)(First)(Middle)
C/O ZEVRA THERAPEUTICS, INC.
101 FEDERAL STREET
(Street)
BOSTON MASSACHUSETTS 02110
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal & Compliance
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/21/2026M66,667A(1)114,792D
Common Stock06/22/2026S(2)34,557D$12.6835(3)80,235D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit(1)06/21/2026M66,667 (4) (4)Common Stock66,667$066,667D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
2. Adoption date of referenced 10b5-1(c) plan is: 01-08-2026.
3. This transaction was executed in multiple trades at prices ranging from $12.53 to $13.19. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
4. The first and second tranches of the restricted stock units vested and settled on June 21, 2025 and June 21, 2026, respectively, and the remaining tranche of the restricted stock units will vest and settle on the next anniversary thereafter, subject to the Reporting person's continued service through such vesting date.
Remarks:
/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Rahsaan W. Thompson06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR